NCT02504528 is a NA clinical trial of house dust mites in Allergic Asthma, sponsored by Guangzhou Institute of Respiratory Disease.

Who is sponsoring NCT02504528?

NCT02504528 is sponsored by Guangzhou Institute of Respiratory Disease.

What drugs are being tested in NCT02504528?

Interventions in NCT02504528: house dust mites.

What condition does NCT02504528 study?

NCT02504528 studies Allergic Asthma.

Is NCT02504528 still recruiting?

NCT02504528 is currently completed. Last updated 19 February 2018.

Last reviewed 2018-02-19 · How we verify

NCT02504528

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchial Allergen Provocation Tests in Asthmatics in Guangzhou

Completed NA Last updated 19 February 2018

What this trial tests

NA trial testing house dust mites in Allergic Asthma in 30 participants. Completed in 1 February 2018.

Timeline

1 July 2015

Primary endpoint
1 July 2017

1 February 2018

Quick facts

Lead sponsor	Guangzhou Institute of Respiratory Disease
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	1 July 2015
Primary completion	1 July 2017
Estimated completion	1 February 2018
Sites	1 location across China

Drugs / interventions tested

house dust mites

Conditions studied

Allergic Asthma — all drugs for Allergic Asthma →

Sponsor

Guangzhou Institute of Respiratory Disease

Who can join

Adults 18 to 60, any sex, with Allergic Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish the methodology of bronchial provocation tests with house dust mites in China, and to evaluate its safety and effects on upper and lower airways inflammation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Response of upper and lower airway inflammation to bronchial challenge with house dust mite in Chinese asthmatics: a pilot study.
Zhu Z, Wang H, Xie Y, An J, et al · · 2021 · cited 1× · PMID 34527337 · DOI 10.21037/jtd-20-2876

Verify or expand the search:

Other recruiting trials for Allergic Asthma

Currently open trials in the same condition.

NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
NCT06438757 — Trial of JYB1904 in Patients With Allergic Asthma · Phase 2 · active not recruiting
NCT06771934 — Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma · active not recruiting

Other Guangzhou Institute of Respiratory Disease trials

Trials by the same sponsor.

NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02504528 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
Last refreshed: 19 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02504528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing